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controlled study of rapid-acting intramuscular
olanzapine in Japanese patients for schizophrenia
with acute agitation
Hideaki Katagiri1*, Shinji Fujikoshi1, Takuya Suzuki2, Kiyoshi Fujita3, Naoya Sugiyama4, Michihiro Takahashi1,6
and Juan-Carlos Gomez5Correction
After the publication of this work [1], we became aware
that it contains inaccurate description. The correct
description on page 5 was “At every timepoint, statisti-
cally significant differences were observed between IM
olanzapine and IM placebo groups (p < .01) (Figure one)”,
and not “At every timepoint, statistically significant
differences were observed between IM olanzapine and
IM placebo groups (p < .001) (Figure one).” We regret any
inconvenience that this inaccuracy might have caused.
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